According to Hong Kong Health Data, Dostalimab (TSR-042) is a humanized monoclonal antibody against PD- 1, which binds to PD- 1 receptor with high affinity, thus blocking its binding to PD-L 1 and PD-L2 ligands.

ARNET(NCT027 15284) recruited patients with dMMR endometrial cancer, whose MMR status was confirmed by IHC, and required the patients to be recurrent or advanced, and had received platinum-containing dual-drug chemotherapy in the past. In the first four cycles, the patient received PD- 1 immunotherapy with doxorubicin 500 mg Q3W, and then doxorubicin 1000 mg Q6W until the disease progressed or the treatment was terminated. The main end points of the study were the objective remission rate (ORR) and the duration of curative effect (DOR), which were evaluated by an independent evaluation committee based on RECIST v 1. 1.65438.

***70 patients with dMMR endometrial cancer were treated with doxorubicin, and their baseline lesions were measurable. As of July 8, 20 19, patients who had been followed up for more than 6 months were included in the interim analysis. The median age of the patients was 64.5 years old, and the ORR was 43%: 9 cases (13%) achieved confirmed complete remission (CR), and 2 cases (30%) achieved confirmed partial remission (PR).